A detailed history of Deep Track Capital, LP transactions in Immunovant, Inc. stock. As of the latest transaction made, Deep Track Capital, LP holds 2,883,736 shares of IMVT stock, worth $79.3 Million. This represents 2.5% of its overall portfolio holdings.

Number of Shares
2,883,736
Previous 493,352 484.52%
Holding current value
$79.3 Million
Previous $15.9 Million 377.6%
% of portfolio
2.5%
Previous 0.53%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$25.1 - $31.61 $60 Million - $75.6 Million
2,390,384 Added 484.52%
2,883,736 $76.1 Million
Q1 2024

May 15, 2024

SELL
$30.27 - $43.79 $15.3 Million - $22.2 Million
-506,648 Reduced 50.66%
493,352 $15.9 Million
Q4 2023

Feb 14, 2024

SELL
$31.31 - $44.19 $56.3 Million - $79.5 Million
-1,797,955 Reduced 64.26%
1,000,000 $42.1 Million
Q3 2023

Nov 14, 2023

SELL
$18.55 - $39.96 $48.7 Million - $105 Million
-2,623,375 Reduced 48.39%
2,797,955 $107 Million
Q2 2023

Aug 14, 2023

SELL
$14.2 - $23.75 $28.6 Million - $47.8 Million
-2,011,387 Reduced 27.06%
5,421,330 $103 Million
Q1 2023

May 15, 2023

SELL
$15.27 - $19.72 $34.8 Million - $44.9 Million
-2,277,283 Reduced 23.45%
7,432,717 $115 Million
Q4 2022

Feb 14, 2023

SELL
$6.59 - $17.75 $990,121 - $2.67 Million
-150,246 Reduced 1.52%
9,710,000 $172 Million
Q3 2022

Nov 14, 2022

BUY
$3.93 - $6.37 $1.59 Million - $2.58 Million
405,246 Added 4.29%
9,860,246 $55 Million
Q2 2022

Aug 12, 2022

BUY
$3.38 - $5.65 $7.54 Million - $12.6 Million
2,230,387 Added 30.87%
9,455,000 $36.9 Million
Q1 2022

May 16, 2022

BUY
$5.06 - $8.77 $12.4 Million - $21.5 Million
2,449,613 Added 51.3%
7,224,613 $39.8 Million
Q4 2021

Feb 14, 2022

BUY
$7.33 - $9.32 $35 Million - $44.5 Million
4,775,000 New
4,775,000 $40.7 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Deep Track Capital, LP Portfolio

Follow Deep Track Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deep Track Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Deep Track Capital, LP with notifications on news.